Toshiki Masuishi - Concepedia

Author

Toshiki Masuishi

Aichi Cancer Center ORCID

Also Known As

Akihito Kawazoe, Masashi Fujii, Masuishi Toshiki, T. Masuishi, TOSHIKI MASUISHI, Tetsuya Etou, Toshiki Masuishi

316

Publications

2.9K

Citations

H-Index

Concepts

All Affiliations

Aichi Cancer Center National Cancer Center Hospital East Shikoku Cancer Center Saitama Cancer Center The University of Texas MD Anderson Cancer Center

About

Toshiki Masuishi is an author at Aichi Cancer Center specializing in oncology, medicine, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	17	28	1.4K
2	Health Sciences	6	6	103
3	Cell Biology	1	1	16
4	Gastroenterology	1	1	15
5	Hepatology	1	1	23

Toshiki Masuishi

Publications

2.4K

Citations

H-Index

Page 1

	Year	Citations
Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial Salvatore Siena, Maria Di Bartolomeo, Kanwal Raghav, The Lancet Oncology OncologyGastrointestinal OncologyColorectal CancerPathologyCancer Treatment	2021	392
Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study Arvind Dasari, Sara Lonardi, Rocio García‐Carbonero, The Lancet OncologyGastrointestinal OncologyColorectal CancerPharmacotherapyCancer Treatment	2023	279
Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial Yoshiaki Nakamura, Wataru Okamoto, Takeshi Kato, Nature Medicine	2021	233
Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer Takayuki Yoshino, Maria Di Bartolomeo, Kanwal Raghav, Nature Communications	2023	138
Prospective Survey of Financial Toxicity Measured by the Comprehensive Score for Financial Toxicity in Japanese Patients With Cancer Kazunori Honda, Bishal Gyawali, Masashi Ando, Journal of Global Oncology	2019	85
Regorafenib Versus Trifluridine/Tipiracil for Refractory Metastatic Colorectal Cancer: A Retrospective Comparison Toshiki Masuishi, Hiroya Taniguchi, Satoshi Hamauchi, Clinical Colorectal Cancer Regorafenib Versus Trifluridine/tipiracilSurgical OncologyRetrospective ComparisonGastrointestinal OncologyMedicine	2016	74
Sotorasib with panitumumab in chemotherapy-refractory KRASG12C-mutated colorectal cancer: a phase 1b trial Yasutoshi Kuboki, Marwan Fakih, John H. Strickler, Nature Medicine Phase 1BOncologyGastrointestinal OncologyColorectal CancerPathology	2024	73
A phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): DESTINY-CRC01. Salvatore Siena, Maria Di Bartolomeo, Kanwal Raghav, Journal of Clinical Oncology ImmunologyImmunoeditingPathologyImmunotherapeuticsImmunotherapy	2020	63
Neutropenia as a Predictive Factor in Metastatic Colorectal Cancer Treated With TAS-102 Satoshi Hamauchi, Kentaro Yamazaki, Toshiki Masuishi, Clinical Colorectal Cancer Predictive FactorGastrointestinal OncologyMedicineColorectal CancerPathology	2016	56
Baseline Sarcopenia and Skeletal Muscle Loss During Chemotherapy Affect Survival Outcomes in Metastatic Gastric Cancer Keiji Sugiyama, Yukiya Narita, Seiichiro Mitani, Anticancer Research	2018	55

Page 1